Back to results
US 8,771,935 B2Granted
Screening methods for cognitive enhancers
AssigneeDart NeuroScience (Cayman) Ltd.
InventorsTimothy P Tully, Roderick E. M. Scott, Rusiko Bourtchouladze
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for identifying cognitive enhancers able to enhance CREB pathway function. Cognitive enhancers identified in accordance with the invention can be used in rehabilitating an animal with cognitive dysfunction and for enhancing memory or normal cognitive performance (ability or function) in the animal.
Claims13
A method comprising:
- 1) screening a plurality of compounds for potential development as-candidate cognitive enhancer compounds by
- 2) determining the ability of said compounds to enhance cyclic adenosine monophosphate (cAMP) response element binding protein (CREB) pathway function wherein said screening and determining comprises the steps of:
- a) contacting cells of neural origin comprising an indicator gene operably linked to a cAMP response element (CRE) promoter with a test compound and with a suboptimal dose of a CREB function stimulating agent simultaneously or sequentially, wherein said CREB function stimulating agent is forskolin;
- b) determining indicator activity in said cells of neural origin which have been contacted with said test compound and with said CREB function stimulating agent, wherein said CREB function stimulating agent is forskolin;
- c) determining indicator activity in said cells of neural origin which have been contacted with said CREB function stimulating agent alone, wherein said CREB function stimulating agent is forskolin;
- d) determining indicator activity in said cells of neural origin which have been contacted with said test compound alone;
- and
- e) determining indicator activity in said cells of neural origin which have not been contacted with said test compound or said CREB function stimulating agent, wherein said CREB function stimulating agent is forskolin;
- f) comparing the indicator activity determined in each of steps b) through e)
- g) selecting said test compound if:
- i) the indicator activity determined in step b) is significantly increased relative to the indicator activity determined in step c);
- and
- ii) the indicator activity determined in step d) is not significantly different relative to the indicator activity determined in step e);
- h) repeating steps a) to g) with a range of different concentrations of said test compound selected in step g);
- and
- i) selecting said test compound if:
- i) the indicator activity determined in step b) is significantly increased relative to the indicator activity determined in step c);
- and
- ii) the indicator activity determined in step d) is not significantly different relative to the indicator activity determined in step e) in the range of different concentrations of said test compound, and
- 3) identifying said test compound as a candidate cognitive enhancer compound if said test compound is selected in steps g) and i).
17 more elements
A method comprising:
- 1) screening a plurality of compounds for potential development as candidate cognitive enhancer compounds by
- 2) determining the ability of said compounds to enhance cyclic adenosine monophosphate (cAMP) response element binding protein (CREB) pathway function wherein said screening and determining comprises the steps of:
- a) contacting host cells comprising an indicator gene operably linked to a cAMP response element (CRE) promoter with a test compound and with a suboptimal dose of a CREB function stimulating agent simultaneously or sequentially, wherein said CREB function stimulating agent is forskolin;
- b) determining indicator activity in said host cells which have been contacted with said test compound and with said CREB function stimulating agent, wherein said CREB function stimulating agent is forskolin;
- c) determining indicator activity in said host cells which have been contacted with said CREB function stimulating agent alone, wherein said CREB function stimulating agent is forskolin;
- d) determining indicator activity in said host cells which have been contacted with said test compound alone;
- and
- e) determining indicator activity in said host cells which have not been contacted with said test compound or said CREB function stimulating agent, wherein said CREB function stimulating agent is forskolin;
- f) comparing the indicator activity determined in each of steps b) through e)
- g) selecting said test compound if:
- i) the indicator activity determined in step b) is increased >100% relative to the indicator activity determined in step c);
- and
- ii) the indicator activity determined in step d) is not significantly different relative to the indicator activity determined in step e);
- and
- h) repeating steps a) to g) with a range of different concentrations of said test compound selected in step g);
- and
- i) selecting said test compound if:
- i) the indicator activity determined in step b) is significantly increased relative to the indicator activity determined in step c);
- and
- ii) the indicator activity determined in step d) is not significantly different relative to the indicator activity determined in step e) in the range of different concentrations of said test compound, and
- 3) identifying said test compound as a candidate cognitive enhancer compound if said test compound is selected in steps g) and i).
18 more elements
Dependencies are inferred from the claim text.